-

insitro to Present at the 44th Annual J.P. Morgan Healthcare Conference

Company Leaders to Participate in Multiple Industry Forums Throughout Healthcare Week

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced that Daphne Koller, Ph.D., founder and CEO, will present a company update, including its AI-enabled discovery engine and therapeutic candidates advancing to the clinic, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, at 4:00 p.m. PT in San Francisco.

Additional insitro participation at healthcare week events:

  • Longwood Healthcare Leaders’ San Francisco CEO Conference
    Daphne Koller, Ph.D., will participate on the panel "Identifying Next-Generation Therapeutics" on Sunday, Jan. 11, at 1:30 p.m. PT
  • KPMG + Goodwin Symposium
    Mary Rozenman, Ph.D., CFO and CBO, will join the panel "Transaction to Transformation: Innovative End-to-End Strategies for Life Sciences Companies Amid Market Volatility" on Wednesday, Jan. 14, at 11:30 a.m. PT.

insitro's J.P. Morgan presentation will be made available on the insitro website following the event.

About insitro

insitro is the AI therapeutics company built on causal biology. By generating an integrated, multimodal corpus of human and cellular data and analyzing it with machine learning, insitro’s platform aims to reveal how disease begins, progresses, and can be resolved. The company applies this approach to identify genetic drivers, prioritize targets, and design medicines intended to treat disease at its root, with programs focused in metabolic disease and neuroscience. insitro is backed by world-class investors and has raised approximately $800M in capital, including approximately $150M from non-dilutive pharma partnerships.

Contacts

Media contact
Eric McKeeby
eric@insitro.com

Industry:

insitro

Release Versions
English

Contacts

Media contact
Eric McKeeby
eric@insitro.com

More News From insitro

insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, an AI company unlocking causal human biology to systematically generate high-value therapeutics to treat grievous illness, today announced a worldwide exclusive research collaboration agreement with AstraZeneca to discover novel targets and therapeutics in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Under the terms of the agreement, insitro will receive $40 million upfront and is eligible for up to approxim...

insitro Designed Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI company unlocking causal human biology to systematically generate high-impact therapeutics, today announced that the advanced machine learning models that insitro built with Eli Lilly and Company (Lilly) to predict in vitro and, critically, in vivo properties of small molecules can now be used by certain biotech companies in Lilly TuneLab™. Trained on multi-species preclinical data that Lilly generated over decades of research from hu...

insitro Appoints Hideo Makimura as Chief Medical Officer to Lead Its Transition to a Clinical-Stage Company

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the appointment of Hideo Makimura as Chief Medical Officer, effective Sept. 14. Makimura will lead clinical development strategy and execution as insitro advances its AI-derived metabolic disease and neuroscience pipeline toward first-in-human trials — a key step in the company’s evolution toward clinical-stage development. Makimura joins as insitro transitions its initial...
Back to Newsroom